ADC Therapeutics SA Adjustments For Unrealised Foreign Exchange Losses Gains
ADC Therapeutics SA (ADCT) reported Adjustments For Unrealised Foreign Exchange Losses Gains of -$124.00 thousand for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Income Statement › Other Income
ifrs-full:AdjustmentsForUnrealisedForeignExchangeLossesGains · last filed 2023-11-07
- ADC Therapeutics SA adjustments for unrealised foreign exchange losses gains for the quarter ending 2023-09-30 was -$214.00K.
- ADC Therapeutics SA adjustments for unrealised foreign exchange losses gains for the quarter ending 2023-06-30 was $72.00K.
- ADC Therapeutics SA adjustments for unrealised foreign exchange losses gains for the quarter ending 2023-03-31 was $18.00K.
- ADC Therapeutics SA adjustments for unrealised foreign exchange losses gains for the quarter ending 2022-12-31 was $215.00K, a 70.63% increase year-over-year.
| Period end | Adjustments For Unrealised Foreign Exchange Losses Gains 3 month | Adjustments For Unrealised Foreign Exchange Losses Gains 6 month | Adjustments For Unrealised Foreign Exchange Losses Gains 9 month | Adjustments For Unrealised Foreign Exchange Losses Gains 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$214.00K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | -$142.00K derived: sum of 2 quarters · filed 2023-11-07 | -$124.00K 6-K · filed 2023-11-07 | $91.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $72.00K derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | $90.00K 6-K · filed 2023-08-08 | $305.00K derived: sum of 3 quarters · filed 2023-08-08 | $255.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | $18.00K 6-K · filed 2023-05-09 | $233.00K derived: sum of 2 quarters · filed 2023-05-09 | $183.00K derived: sum of 3 quarters · filed 2023-11-07 | -$26.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | $215.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $165.00K derived: sum of 2 quarters · filed 2023-11-07 | -$44.00K derived: sum of 3 quarters · filed 2023-11-07 | -$107.00K 20-F · filed 2023-03-15 |
| 2022-09-30 | -$50.00K derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | -$259.00K derived: sum of 2 quarters · filed 2023-11-07 | -$322.00K 6-K · filed 2023-11-07 | -$196.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$209.00K derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | -$272.00K 6-K · filed 2023-08-08 | -$146.00K derived: sum of 3 quarters · filed 2023-08-08 | -$206.00K derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$63.00K 6-K · filed 2023-05-09 | $63.00K derived: sum of 2 quarters · filed 2023-05-09 | $3.00K derived: sum of 3 quarters · filed 2023-05-09 | $118.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $126.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $66.00K derived: sum of 2 quarters · filed 2023-03-15 | $181.00K derived: sum of 3 quarters · filed 2023-03-15 | -$185.00K 20-F · filed 2023-03-15 |
| 2021-09-30 | -$60.00K derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08 | $55.00K derived: sum of 2 quarters · filed 2022-11-08 | -$311.00K 6-K · filed 2022-11-08 | $165.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $115.00K derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09 | -$251.00K 6-K · filed 2022-08-09 | $225.00K derived: sum of 3 quarters · filed 2023-03-15 | $225.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$366.00K 6-K · filed 2022-05-09 | $110.00K derived: sum of 2 quarters · filed 2023-03-15 | $110.00K derived: sum of 3 quarters · filed 2023-03-15 | $118.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $476.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $476.00K derived: sum of 2 quarters · filed 2023-03-15 | $484.00K derived: sum of 3 quarters · filed 2023-03-15 | $476.00K 20-F · filed 2023-03-15 |
| 2020-09-30 | $0.00 derived: 6-K 9 month − 6-K 6 month · filed 2021-11-02 | $8.00K derived: sum of 2 quarters · filed 2021-11-02 | $0.00 6-K · filed 2021-11-02 | |
| 2020-06-30 | $8.00K derived: 6-K 6 month − 6-K 3 month · filed 2021-08-03 | $0.00 6-K · filed 2021-08-03 | ||
| 2020-03-31 | -$8.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $128.00K 20-F · filed 2022-03-17 | |||
| 2018-12-31 | -$29.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |